Effects of Prophylactic Indomethacin in Extremely Low-Birth-Weight Infants With and Without Adequate Exposure to Antenatal Corticosteroids
Open Access
- 1 July 2011
- journal article
- research article
- Published by American Medical Association (AMA) in Archives of Pediatrics & Adolescent Medicine
- Vol. 165 (7) , 642-646
Abstract
ObjectiveTo examine whether treatment with antenatal corticosteroids modifies the immediate and long-term effects of prophylactic indomethacin sodium trihydrate in extremely low-birth-weight infants.DesignPost hoc subgroup analysis of data from the Trial of Indomethacin Prophylaxis in Preterms.SettingThirty-two neonatal intensive care units in Canada, the United States, Australia, New Zealand, and Hong Kong.ParticipantsA total of 1195 infants with birth weights of 500 to 999 g and known exposure to antenatal corticosteroids. We defined as adequate any exposure to antenatal corticosteroids that occurred at least 24 hours before delivery.InterventionIndomethacin or placebo intravenously once daily for the first 3 days.Outcome MeasuresDeath or survival to 18 months with cerebral palsy, cognitive delay, severe hearing loss, or bilateral blindness; severe periventricular and intraventricular hemorrhage; patent ductus arteriosus; and surgical closure of a patent ductus arteriosus.ResultsOf the 1195 infants in this analysis cohort, 670 had adequate and 525 had inadequate exposure to antenatal corticosteroids. There was little statistical evidence of heterogeneity in the effects of prophylactic indomethacin between the subgroups for any of the outcomes. The adjusted P values for interaction were as low as .15 for the outcome of death or impairment at 18 months and as high as .80 for the outcome of surgical duct closure.ConclusionWe find little evidence that the effects of prophylactic indomethacin vary in extremely low-birth-weight infants with and without adequate exposure to antenatal corticosteroids.Trial Registrationclinicaltrials.gov Identifier: NCT00009646Keywords
This publication has 12 references indexed in Scilit:
- Prophylactic intravenous indomethacin for preventing mortality and morbidity in preterm infantsCochrane Database of Systematic Reviews, 2010
- Treatment of persistent patent ductus arteriosus in preterm infants: time to accept the null hypothesis?Journal of Perinatology, 2010
- Statistics in Medicine — Reporting of Subgroup Analyses in Clinical TrialsNew England Journal of Medicine, 2007
- Indomethacin Prophylaxis for Preterm Infants: The Impact of 2 Multicentered Randomized Controlled Trials on Clinical PracticeThe Journal of Pediatrics, 2007
- Retrospective economic evaluation of a controlled trial of indomethacin prophylaxis for patent ductus arteriosus in premature infantsEarly Human Development, 2006
- Male/Female Differences in Indomethacin Effects in Preterm InfantsThe Journal of Pediatrics, 2005
- Prevention of intraventricular hemorrhage by indomethacin in male preterm infantsThe Journal of Pediatrics, 2004
- Patency of the ductus arteriosus in the premature infant: is it pathologic? Should it be treated?Current Opinion in Pediatrics, 2004
- Improved outcome of preterm infants when delivered in tertiary care centersObstetrics & Gynecology, 2001
- Long-Term Effects of Indomethacin Prophylaxis in Extremely-Low-Birth-Weight InfantsNew England Journal of Medicine, 2001